Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma

IUBMB Life

Volumn 65, Issue 9, 2013, Pages 748-758

  Wang, Ao Xue ^a   Qi, Xiao Yi ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

BRAF inhibitor; MEK; melanoma; resistance; signaling

Indexed keywords

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; 2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; B RAF KINASE; B RAF KINASE INHIBITOR; CARBOPLATIN; CHIR 265; CYCLIN D1; DABRAFENIB; DACARBAZINE; KI 67 ANTIGEN; LGX 818; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; N RAS PROTEIN; PACLITAXEL; PLACEBO; RAF PROTEIN; RAS PROTEIN; RG 704; SORAFENIB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; XL 281;

ARTHRALGIA; BRAIN METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; DRUG ERUPTION; FATIGUE; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; OVERALL SURVIVAL; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SKIN CARCINOMA;

BRAF INHIBITOR; MEK; MELANOMA; RESISTANCE; SIGNALING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RAF KINASES; RAS PROTEINS; SKIN NEOPLASMS;

EID: 84883214066     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1193     Document Type: Review

References (79)

1. Mimeault, M., and, Batra, S. K., (2012) Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J. Clin. Oncol. 3, 32-42.
2. Yee, V. S., Thompson, J. F., McKinnon, J. G., Scolyer, R. A., Li, L. X., et al. (2005) Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann. Surg. Oncol. 12, 429-439.
3. Berwick, M., Erdei, E., and, Hay, J., (2009) Melanoma epidemiology and public health. Dermatol. Clin. 27, 205-214, viii.
4. Patel, P. M., Suciu, S., Mortier, L., Kruit, W. H., Robert, C., et al. (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur. J. Cancer 47, 1476-1483.
5. Eggermont, A. M., and, Robert, C., (2011) New drugs in melanoma: it's a whole new world. Eur. J. Cancer 47, 2150-2157.
6. Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., et al. (2012) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139.
7. Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096.
8. Flaherty, K. T., (2012) Targeting metastatic melanoma. Annu. Rev. Med. 63, 171-183.
9. McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W., et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 1263-1284.
10. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
11. Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., et al. (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
12. Smalley, K. S., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., et al. (2009) CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28, 85-94.
13. Dumaz, N., (2011) Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases 2, 289-292.
14. Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., et al. (2004) V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342.
15. Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., et al. (2010) RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527.
16. Pritchard, C. A., Hayes, L., Wojnowski, L., Zimmer, A., Marais, R. M., et al. (2004) B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol. Cell Biol. 24, 5937-5952.
17. Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J. Y., Wong, L., et al. (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66, 999-1006.
18. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
19. Michaloglou, C., Vredeveld, L. C., Soengas, M. S., Denoyelle, C., Kuilman, T., et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
20. Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
21. Gopal, Y. N., Deng, W., Woodman, S. E., Komurov, K., Ram, P., et al. (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 70, 8736-8747.
22. Jiang, C. C., Lai, F., Thorne, R. F., Yang, F., Liu, H., et al. (2011) MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin. Cancer Res. 17, 721-730.
23. Ellerhorst, J. A., Greene, V. R., Ekmekcioglu, S., Warneke, C. L., Johnson, M. M., et al. (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res. 17, 229-235.
24. Ji, Z., Flaherty, K. T., and, Tsao, H., (2010) Molecular therapeutic approaches to melanoma. Mol. Aspects Med. 31, 194-204.
25. VanBrocklin, M. W., Robinson, J. P., Lastwika, K. J., Khoury, J. D., and, Holmen, S. L., (2010) Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. Pigment Cell Melanoma Res. 23, 531-541.
26. Byron, S. A., Loch, D. C., Wellens, C. L., Wortmann, A., Wu, J., et al. (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol. Cancer 11, 75.
27. Qin, J., Xin, H., and, Nickoloff, B. J., (2012) Specifically targeting ERK1 or ERK2 kills melanoma cells. J. Transl. Med. 10, 15.
28. Young, A., Lyons, J., Miller, A. L., Phan, V. T., Alarcon, I. R., et al. (2009) Ras signaling and therapies. Adv. Cancer Res. 102, 1-17.
29. Balmanno, K., and, Cook, S. J., (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16, 368-377.
30. Arozarena, I., Sanchez-Laorden, B., Packer, L., Hidalgo-Carcedo, C., Hayward, R., et al. (2011) Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19, 45-57.
31. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109.
32. Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., et al. (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 2412-2421.
33. Flaherty, K. T., Schiller, J., Schuchter, L. M., Liu, G., Tuveson, D. A., et al. (2008) A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14, 4836-4842.
34. McDermott, D. F., Sosman, J. A., Gonzalez, R., Hodi, F. S., Linette, G. P., et al. (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group. J. Clin. Oncol. 26, 2178-2185.
35. Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., et al. (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823-2830.
36. Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., et al. (2009) Small molecules and targeted therapies in distant metastatic disease. Ann. Oncol. 20 (suppl), vi35-vi40.
37. Tseng, J. R., Stuart, D., Aardalen, K., Kaplan, A., Aziz, N., et al. (2011) Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor. Neoplasia 13, 266-275.
38. Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., et al. (2012) RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res. 18, 2184-2198.
39. Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 105, 3041-3046.
40. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
41. Huang, T., Karsy, M., Zhuge, J., Zhong, M., and, Liu, D., (2013) B-Raf and the inhibitors: from bench to bedside. J. Hematol. Oncol. 6, 30.
42. Lee, J. T., Li, L., Brafford, P. A., van den Eijnden, M., Halloran, M. B., et al. (2010) PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820-827.
43. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., and, Rosen, N., (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
44. Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., et al. (2010) PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190-200.
45. Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
46. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
47. Khattak, M., Fisher, R., Turajlic, S., and, Larkin, J., (2013) Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther. Adv. Med. Oncol. 5, 105-118.
48. Fedorenko, I. V., Paraiso, K. H., and, Smalley, K. S., (2011) Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem. Pharmacol. 82, 201-209.
49. Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., et al. (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
50. Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., et al. (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
51. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
52. LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., et al. (2010) Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. 16, 1924-1937.
53. Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., et al. (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209-2219.
54. Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146.
55. Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., et al. (2011) Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555-567.
56. Greger, J. G., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., et al. (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11, 909-920.
57. Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., et al. (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782-789.
58. Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114.
59. Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
60. Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., et al. (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256.
61. Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., et al. (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 18, 2316-2325.
62. Karasic, T. B., Hei, T. K., and, Ivanov, V. N., (2010) Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp. Cell Res. 316, 1994-2007.
63. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
64. Joseph, R. W., Sullivan, R. J., Harrell, R., Stemke-Hale, K., Panka, D., et al. (2012) Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J. Immunother. 35, 66-72.
65. Smalley, K. S., Lioni, M., Dalla Palma, M., Xiao, M., Desai, B., et al. (2008) Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 7, 2876-2883.
66. Tap, W. D., Gong, K. W., Dering, J., Tseng, Y., Ginther, C., et al. (2010) Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12, 637-649.
67. Paraiso, K. H., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760.
68. Shao, Y., and, Aplin, A. E., (2010) Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70, 6670-6681.
69. Rahimi, A. S., Wilson, D. D., Saylor, D. K., Stelow, E. B., Thomas, C. Y., et al. (2012) p16, Cyclin D1, and HIF-1alpha predict outcomes of patients with oropharyngeal squamous cell carcinoma treated with definitive intensity-modulated radiation therapy. Int. J. Otolaryngol. 2012, 685951.
70. Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
71. Whittaker, S., Kirk, R., Hayward, R., Zambon, A., Viros, A., et al. (2010) Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci. Transl. Med. 2, 35ra41.
72. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
73. Tsao, H., Chin, L., Garraway, L. A., and, Fisher, D. E., (2012) Melanoma: from mutations to medicine. Genes Dev. 26, 1131-1155.
74. Brana, I., and, Siu, L. L., (2012) Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med. 10, 161.
75. Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390.
76. Shi, H., Kong, X., Ribas, A., and, Lo, R. S., (2011) Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 71, 5067-5074.
77. Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
78. Yang, J. Y., Chang, C. J., Xia, W., Wang, Y., Wong, K. K., et al. (2010) Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res. 70, 4709-4718.
79. Hatzivassiliou, G., Liu, B., O'Brien, C., Spoerke, J. M., Hoeflich, K. P., et al. (2012) ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11, 1143-1154.